Patents Examined by Larry R. Helms
  • Patent number: 8629253
    Abstract: Nucleic acids encoding tRNA synthetase polypeptides useful for regulating angiogenesis are disclosed. Methods of making and using such nucleic acids are also disclosed.
    Type: Grant
    Filed: October 31, 2006
    Date of Patent: January 14, 2014
    Assignee: The Scripps Research Institute
    Inventors: Paul Schimmel, Keisuke Wakasugi
  • Patent number: 7968695
    Abstract: The present invention provides the recombinant cloning and sequencing of two of the major Eimeria maxima gametocyte antigens having molecular weights of 56 and 82 kDa and the expression of these recombinant antigens in an E. coli expression system using the plasmid pTrcHis. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen. The subject invention also provides two 30 kDa proteins and three 14 kDa proteins from Eimeria maxima gametocytes having at the N-terminal end the amino acid sequence described herein. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen and any of the aforementioned proteins.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: June 28, 2011
    Assignee: Abic Biological Laboratories Ltd.
    Inventors: Sabina I. Belli, Nicholas C. Smith, Michael Wallach
  • Patent number: 7964200
    Abstract: The present invention relates, in part, to methods and compositions for immunizing against infection by Chlamydia trachomatis. The methods and compositions rely, in part, on administering an immunogenic composition comprising one or more peptides derived from C. trachomatis major outer membrane protein (MOMP) to a subject to be immunized. In some embodiments, the compositions comprise a chimeric immunogen comprising a receptor binding domain, a translocation domain, and a Chlamydia trachomatis antigen. Polynucleotides encoding the chimeric immunogens, expression vectors comprising the polynucleotides, and kits comprising the compositions are also provided.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: June 21, 2011
    Assignee: Children's Hospital & Research Center at Oakland
    Inventors: Randall J. Mrsny, Deborah Dean
  • Patent number: 7960505
    Abstract: The present invention provides isolated lantibiotics that inhibit Gram negative and Gram positive microbes. The lantibiotic includes an amino acid sequence, wherein the amino acid sequence of the compound and the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:22 have at least 80% identity. The lantibiotics have the characteristic of inhibiting growth of a Gram negative microbe in conditions that do not damage the outer membrane of the Gram negative microbe. The present invention also provides methods for making and using the lantibiotics.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: June 14, 2011
    Assignee: Regents of the University of Minnesota
    Inventors: Daniel J. O'Sullivan, Ju-Hoon Lee
  • Patent number: 7951375
    Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: May 31, 2011
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Pia M. Challita-Eid, Mary Faris, Wangmao Ge, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Arthur B. Raitano, Daniel E. H. Afar
  • Patent number: 7947496
    Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: May 24, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto, Fortunata McConkey
  • Patent number: 7919233
    Abstract: The invention relates to a method of identifying modulators of programmed cell death, comprising an interaction between a motif of Beclin protein and an anti-apoptotic member of the family of Bcl-2 proteins and the detection of said interaction be means of fluorescence polarization. The modulators identified on the basis of said method are administered to cancer patients in order to induce apoptotic- and/or autophagic-type programmed cell death. The invention also relates to a motif of the Beclin protein which can interact with an anti-apoptic member of the family of Bcl-2 proteins and to the use thereof in order to induce programmed cell death in a cancer patient.
    Type: Grant
    Filed: January 31, 2006
    Date of Patent: April 5, 2011
    Assignee: Les Laboratoires Servier
    Inventors: Olivier Geneste, John Hickman, Jean-Christophe Rain
  • Patent number: 7897329
    Abstract: The present invention features a method for determining t-RNA dihydrouridine-synthase activity of a polypeptide and screening for modulators of t-RNA dihydrouridine-synthase activity. The present invention further provides methods or pharmaceutical compositions for preventing and/or treating non-small cell lung cancer (NSCLC) using such modulators. Furthermore, the present invention provides methods for diagnosing non-small cell lung cancer (NSCLC) using the t-RNA dihydrouridine-synthase activity of IMS-E21 (URLC8) protein as an index. The present invention further provides methods for predicting and prognosing lung squamous-cell carcinoma (SCC).
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: March 1, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • Patent number: 7888005
    Abstract: The present invention relates generally to methods, kits, compositions, and combinations to identify anti-infective or anti-pathogenic agents. The present invention also relates to methods, kits, compositions, and combinations directed to identifying elements of RNA metabolism related to pathogen propagation, monitoring of these RNA metabolic events, and to agents capable of interrupting RNA metabolism in a pathogen-specific fashion.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: February 15, 2011
    Assignee: The Curators of the University of Missouri
    Inventors: Francis J. Schmidt, Farahnaz Rahmatpanah
  • Patent number: 7887818
    Abstract: Neospora caninum is the causal agent of bovine neosporosis which results in high levels of abortion. The protective efficacy of two Neospora antigens: Neospora cyclophilin (NcCyP) and NcSRS2 was evaluated. Mice vaccinated with recombinant (r) NcCyP, rNcSRS2, and the combination rNcCyP plus rNcSRS2, formulated with adjuvant ImmuMax-SR® and CpG were challenge-infected 3 weeks following the booster immunization and necropsied 3 weeks after the challenge infection. Mice vaccinated with rNcCyP, rNcSRS2, or the combination of rNcCyP and rNcSRS2 responded with high levels of NcCyP- or NcSRS2- specific antibodies. Mice which received vaccines formulated with either rNcCyP or the combination rNcCyP and rNcSRS2 had a higher (p<0.01) percent protection when compared to the mock- or non-vaccinated mice. Groups immunized with rNcSRS2 alone exhibited slightly lower levels of protection. Results indicate that NcCyP is a highly efficacious vaccine candidate useful in protection against Neospora infection.
    Type: Grant
    Filed: February 20, 2008
    Date of Patent: February 15, 2011
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Wenbin Tuo, Mark C. Jenkins, Yan Zhao
  • Patent number: 7887817
    Abstract: A process for preventing a protozoal disease by the administration of an alkyl phosphocholine to a human being.
    Type: Grant
    Filed: January 8, 2003
    Date of Patent: February 15, 2011
    Assignee: AEterna Zentaris GmbH
    Inventor: Jürgen Engel
  • Patent number: 7888468
    Abstract: Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death or uncontrolled growth. The present inventors have found that different microorganisms produce different cytotoxic factor(s) having anticancer activity. The substantially pure cytotoxic factors can be used in a method of treating an infectious disease or a cancer.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: February 15, 2011
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Ananda M. Chakrabarty, Tapas K. Das Gupta, Vasu Punj, Olga Zaborina, Yoshinori Hiraoka, Tohru Yamada
  • Patent number: 7888054
    Abstract: The invention provides Ehrlichia canis antigens that can be used to detect E. canis infected animals regardless of whether the animals have been vaccinated for E. canis. The invention also provides compositions and methods for determining the presence of E. canis antigens and antibodies.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: February 15, 2011
    Assignee: IDEXX Laboratories, Inc.
    Inventors: Eugene Regis Krah, III, Melissa Beall, Thomas Patrick O'Connor, Jr., Ramaswamy Chandrashekar
  • Patent number: 7883710
    Abstract: This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies.
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: February 8, 2011
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Bernard W. Beall, George M. Carlone, Jacquelyn S. Sampson, Edwin W. Ades
  • Patent number: 7875438
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: January 25, 2011
    Assignee: Sanofi Pasteur Limited/Sanofi Pasteur Limitee
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Patent number: 7875439
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: January 25, 2011
    Assignees: Sanofi Pasteur Limited, Sanofi Pasteur Limitee
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Patent number: 7875437
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: January 25, 2011
    Assignee: Sanofi Pasteur Limited/Sanofi Pasteur Limitee
    Inventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
  • Patent number: 7871779
    Abstract: Novel techniques for the detection of Aspergillus in samples are disclosed. These techniques relate to PCR amplification and/or detection of Aspergillus ITS1 rDNA sequences, and the identification of particular species of Aspergillus by detecting differences in the ITS1-V1, ITS-V2, ITS-V3, ITS-V4, and ITS-V5 nucleic acid sequences of Aspergillus. The highly variable regions of the ITS1 rDNA sequences are particularly useful in distinguishing, for example, Aspergillus clavatus, Aspergillus granulosus, Aspergillus sydowii, Aspergillus flavipes, Aspergillus restrictus, Aspergillus versicolor, Aspergillus wentii, and Aspergillus chevalieri. In particular embodiments, the sequence differences are also able to distinguish among variants of particular species, such as Aspergillus granulosus CBS 119.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: January 18, 2011
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Christine J. Morrison, Hans Peter Hinrikson
  • Patent number: 7871763
    Abstract: Genes up-regulated in hepatocellular carcinomas and polypeptides encoded by these genes are provided. Vectors, transformants and methods for producing the recombinant polypeptides are also provided. Probes and primers of these genes and antibodies against the polypeptides are also provided. The probes, primers and antibodies can be used as reagents for detecting hepatocellular carcinomas. Methods for detecting hepatocellular carcinomas using such detection reagents are further provided. Antisense nucleotide sequences of these genes are also provided and can be used to inhibit growth of hepatocellular carcinomas.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: January 18, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa
  • Patent number: 7867501
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: January 11, 2011
    Assignee: Sanofi Pasteur Limited/Sanofi Pasteur Limitee
    Inventors: Lynn Doucette-Stamm, David Bush, Oiandong Zeng, Timothy Opperman, Chad Eric Houseweart